Several selective CHEK1 inhibitors, including Prexasertib, SRA737, and others, have been developed, and early-phase clinical trials have identified the potential therapeutic effects of these modalities in MM [45–47]. The gene discussed is CHEK1; the disease is Miyoshi myopathy.